Requires certain disclosures by providers of commercial financing.
A4580 would create a commercial financing disclosure regime in New Jersey for business-purpose financing products, including sales-based financing, closed-end financing, open-end financing, factoring transactions, and certain finance leases. The bill defines key terms such as provider, broker, recipient, finance charge, and specific offer, and requires providers to give standardized, clear disclosures at the time a specific offer is made. Those disclosures generally include the amount financed, finance charge, APR or estimated APR, total repayment amount, term, payment amounts, other fees, prepayment/refinance terms, and collateral or security interests.
The bill also authorizes the Commissioner of Banking and Insurance to adopt implementing regulations, prescribe disclosure forms, and require disclosures for other commercial financing products not specifically listed. It imposes separate disclosure obligations on brokers that charge fees or commissions paid by the recipient, and it requires written or electronic recipient signatures on the required disclosures before the transaction can proceed. The bill includes enforcement provisions, civil penalties, and limited safe-harbor language for certain disclosure errors and for post-closing changes in sales-based financing that result solely from actual sales fluctuations.
The bill would supplement New Jersey’s banking and insurance laws by adding a new set of disclosure requirements for commercial financing transactions, while expressly excluding certain transactions and parties such as financial institutions, Farm Credit Act lenders, real-property-secured financing, small-volume providers, transactions over $500,000, and specified health-care receivables factoring. It would also bring finance leases within the scope of the disclosure rules while excluding ordinary leases, and it would require the Department of Banking and Insurance to promulgate regulations to implement the act. Providers and brokers that violate the act could face civil penalties, and courts or the commissioner could order additional relief in cases of reckless or willful violations.
The bill appears to be generally consumer- and small-business-protective in tone, with its core purpose being to improve transparency in commercial financing and make pricing terms easier to compare. The statement indicates the bill is intended to align New Jersey with similar disclosure regimes adopted in other states, suggesting a regulatory harmonization approach rather than a novel or punitive one. No committee transcripts or votes were provided, so there is no recorded legislative debate or formal vote history to indicate broader support or opposition.
The main points of potential contention are the breadth of the disclosure requirements, the inclusion of finance leases, and the treatment of sales-based financing. Providers and brokers may view the mandated APR calculations, estimated APR methodology, signature requirements, and broker-specific disclosures as administratively burdensome, especially for products with variable repayment tied to revenue. The bill also removes an option previously available for factoring and sales-based financing to disclose estimated yearly total dollar cost instead of APR, which could be controversial for lenders who argue APR is harder to present accurately for those products. Another possible issue is the bill’s exemption structure, particularly the carve-outs for financial institutions and certain health-care receivables transactions, which may be seen as either necessary tailoring or uneven treatment depending on the stakeholder.